Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.

Abstract

Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor beta gene (PDGFRB). We used imatinib to treat a 49-year old man with atypical CMD in accelerated phase and the H4 (D10S170)-PDGFRB fusion gene. After 3 months of treatment, we observed grade 4 hematologic toxicity and a lack of response.

• Authors: Jean-Noël Bastie, Isabel Garcia, Christine Terré, Nicholas C P Cross, Francois-Xavier Mahon, Sylvie Castaigne
• Journal: Haematologica (Haematologica) Vol. 89 Issue 10 Pg. 1263-4 (Oct 2004) ISSN: 1592-8721 [Electronic] Italy
• PMID: 15477214 (Publication Type: Case Reports, Letter)

Chemical References

• Benzamides
• Biomarkers
• Enzyme Inhibitors
• H4-PDGFRB fusion protein, human
• Mutant Proteins
• Oncogene Proteins, Fusion
• Piperazines
• Pyrimidines
• Imatinib Mesylate
• Hydroxyurea

Topics

• Benzamides
• Biomarkers
• Chromosomes, Human, Pair 10 (genetics, ultrastructure)
• Chromosomes, Human, Pair 5 (genetics, ultrastructure)
• Disease Progression
• Drug Resistance
• Enzyme Inhibitors (adverse effects, pharmacology, therapeutic use)
• Gene Rearrangement
• Humans
• Hydroxyurea (therapeutic use)
• Imatinib Mesylate
• Leukocytosis (drug therapy, etiology)
• Male
• Middle Aged
• Mutant Proteins (genetics)
• Oncogene Proteins, Fusion
• Piperazines (adverse effects, pharmacology, therapeutic use)
• Primary Myelofibrosis (complications, drug therapy, genetics)
• Pyrimidines (adverse effects, pharmacology, therapeutic use)
• Splenectomy
• Splenomegaly (etiology, surgery)
• Thrombocytopenia (chemically induced, etiology)
• Translocation, Genetic
• Treatment Failure